PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

on behalf of the International cSLE T2T Task Force

doi:10.1016/j.clim.2023.109296

PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

on behalf of the International cSLE T2T Task Force

Pediatrics

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Objective: To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials. Methods: The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria. Results: The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0–3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics. Conclusions: A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.

Original language	English (US)
Article number	109296
Journal	Clinical Immunology
Volume	250
DOIs	https://doi.org/10.1016/j.clim.2023.109296
State	Published - May 2023

Keywords

Childhood-SLE
Low disease activity
T2T
Treat-to-target
cLLDAS
cSLE

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.clim.2023.109296

Cite this

@article{a52b95fa833049d6bee578ca5dbfaa4b,

title = "PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)",

abstract = "Objective: To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials. Methods: The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria. Results: The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0–3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics. Conclusions: A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.",

keywords = "Childhood-SLE, Low disease activity, T2T, Treat-to-target, cLLDAS, cSLE",

author = "{on behalf of the International cSLE T2T Task Force} and Smith, {E. M.D.} and A. Aggarwal and J. Ainsworth and E. Al-Abadi and T. Avcin and L. Bortey and J. Burnham and C. Ciurtin and Hedrich, {C. M.} and S. Kamphuis and L. Lambert and Levy, {D. M.} and L. Lewandowski and N. Maxwell and E. Morand and S. Ozen and Pain, {C. E.} and A. Ravelli and {Saad Magalhaes}, C. and C. Pilkington and D. Schonenberg-Meinema and C. Scott and K. Tullus and Beresford, {M. W.} and B. Goilav and S. Marks and L. Oni",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = may,

doi = "10.1016/j.clim.2023.109296",

language = "English (US)",

volume = "250",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

AU - on behalf of the International cSLE T2T Task Force

AU - Smith, E. M.D.

AU - Aggarwal, A.

AU - Ainsworth, J.

AU - Al-Abadi, E.

AU - Avcin, T.

AU - Bortey, L.

AU - Burnham, J.

AU - Ciurtin, C.

AU - Hedrich, C. M.

AU - Kamphuis, S.

AU - Lambert, L.

AU - Levy, D. M.

AU - Lewandowski, L.

AU - Maxwell, N.

AU - Morand, E.

AU - Ozen, S.

AU - Pain, C. E.

AU - Ravelli, A.

AU - Saad Magalhaes, C.

AU - Pilkington, C.

AU - Schonenberg-Meinema, D.

AU - Scott, C.

AU - Tullus, K.

AU - Beresford, M. W.

AU - Goilav, B.

AU - Marks, S.

AU - Oni, L.

PY - 2023/5

Y1 - 2023/5

N2 - Objective: To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials. Methods: The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria. Results: The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0–3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics. Conclusions: A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.

AB - Objective: To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials. Methods: The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria. Results: The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0–3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics. Conclusions: A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.

KW - Childhood-SLE

KW - Low disease activity

KW - T2T

KW - Treat-to-target

KW - cLLDAS

KW - cSLE

UR - http://www.scopus.com/inward/record.url?scp=85151278990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151278990&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2023.109296

DO - 10.1016/j.clim.2023.109296

M3 - Article

C2 - 36934849

AN - SCOPUS:85151278990

SN - 1521-6616

VL - 250

JO - Clinical Immunology

JF - Clinical Immunology

M1 - 109296

ER -

PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this